PF530

PF530 is a name associated with two distinct drug candidates in the pharmaceutical industry. 1. **Granisetron extended-release injection**: In one context, PF530 refers to a unique formulation of **granisetron**, a selective serotonin 5-HT3 receptor antagonist used to prevent nausea and vomiting caused by chemotherapy and surgery. This formulation, developed by A.P. Pharma (later Heron Therapeutics), utilizes the proprietary Biochronomer drug delivery technology to provide sustained therapeutic drug levels[1]. 2. **Biosimilar interferon beta-1b**: In another context, PF530 refers to a **biosimilar to interferon beta-1b (the reference product is Betaseron)** developed by Pfenex for the treatment of relapsing forms of multiple sclerosis. Because the question is exactly "PF530" with no further context, both associations are noted, but the strongest and most frequently cited usage in recent years is as the biosimilar to interferon beta-1b per several company and regulatory filings[2][9].

Brand names

PF530PF-530PF 530

Other names

PF530PF-530PF 530